表紙
市場調査レポート

Rigel Pharmaceuticals, Inc.の製品パイプライン分析

Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 226229
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Rigel Pharmaceuticals, Inc.の製品パイプライン分析 Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年05月29日 ページ情報: 英文 38 Pages
概要

Rigel Pharmaceuticals, Inc.は、炎症性疾患および自己免疫疾患治療用の小分子医薬品を発見、開発する臨床段階の医薬品開発企業です。

当レポートでは、Rigel Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Rigel Pharmaceuticals, Inc.の基本情報

Rigel Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Rigel Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Rigel Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Rigel Pharmaceuticals, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Rigel Pharmaceuticals, Inc.:薬剤プロファイル

  • fostamatinib disodium
  • R-348
  • R-118
  • Atropy阻害剤
  • PKCソータ阻害剤プログラム

Rigel Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Rigel Pharmaceuticals, Inc.:最近のパイプライン動向

Rigel Pharmaceuticals, Inc.:休止中のプロジェクト

Rigel Pharmaceuticals, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • fostamatinib disodium
  • R-333
  • R-343
  • R-548

Rigel Pharmaceuticals, Inc.:企業発表

Rigel Pharmaceuticals, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07131CDB

Summary

Global Markets Direct's, 'Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Rigel Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rigel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Rigel Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Rigel Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Rigel Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Rigel Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Rigel Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Rigel Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Rigel Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rigel Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Rigel Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Rigel Pharmaceuticals, Inc. Snapshot
    • Rigel Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Rigel Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Rigel Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Rigel Pharmaceuticals, Inc. - Pipeline Products Glance
    • Rigel Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Rigel Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Rigel Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Rigel Pharmaceuticals, Inc. - Drug Profiles
    • fostamatinib disodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Growth and Differentiation Factor 8 for Ventilator Atrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TGF Beta Receptor for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Rigel Pharmaceuticals, Inc. - Pipeline Analysis
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Target
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Rigel Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Rigel Pharmaceuticals, Inc. - Dormant Projects
  • Rigel Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • fostamatinib disodium
      • R-333
      • R-548
  • Rigel Pharmaceuticals, Inc. - Company Statement
  • Rigel Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Rigel Pharmaceuticals, Inc., Key Information
  • Rigel Pharmaceuticals, Inc., Key Facts
  • Rigel Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rigel Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Rigel Pharmaceuticals, Inc. - Phase III, 2015
  • Rigel Pharmaceuticals, Inc. - Phase II, 2015
  • Rigel Pharmaceuticals, Inc. - Preclinical, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Rigel Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Rigel Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Rigel Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rigel Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top